key: cord-0842488-4ue6bife authors: Danlos, F.X.; Ackermann, F.; Rohmer, J.; Roumier, M.; Marabelle, A.; Michot, J.M. title: High levels of TNFα in patients with COVID-19 refractory to tocilizumab date: 2021-03-20 journal: Eur J Cancer DOI: 10.1016/j.ejca.2021.01.056 sha: 888411bd04244b55f86fb2da31637bc80923217f doc_id: 842488 cord_uid: 4ue6bife nan TNF-α levels were measured in serum collected from Healthy controls and COVID-19 patients before ( "baseline") and 7 days after tocilizumab. Data shown are those of all the patients treated with tocilizumab and who were able to provide a pre-treatment (baseline) and post-treatment serum (up to date serum +7). Of the 25 patients treated with tocilizumab, pre-and post-treatment serum analyzes were available for 18 patients represented according to their outcome; mortality before day 30 (left panel) and response to tocilizumab (right panel). Baseline TNF-α serum levels were significantly higher at baseline in patients who eventually died of Covid19 (left panel). Post tocilizumab TNF-α serum levels were significantly increasing in patients who did not favorably respond to tocilizumab (right panel). ☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ☒The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Over the last 5 years, AM and JMM have participated as principal investigators and sub-investigators of oncology clinical trials sponsored by manufacturers of anti-IL6 and anti-IL6R therapies Roche/Genentech, Sanofi/Regeneron, J&J/Janssen. AM has received honoraria from Roche/Genentech, J&J and Sanofi for consulting in the field of cancer immunotherapy. AM has received grants for oncology research from Sanofi. Gustave Roussy has received funding, grants and drug supply from Roche/Genentech, Sanofi/Regeneron, Janssen for running clinical trials or research projects in oncology. FXD, FA, JR and MR have no conflict of interest to disclose. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia Tocilizumab in patients with severe COVID-19: a retrospective cohort study Effective treatment of severe COVID-19 patients with tocilizumab Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19 An inflammatory cytokine signature predicts COVID-19 severity and survival A minimal common outcome measure set for COVID-19 clinical research Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19 Acknowledgements: we would like to thank the following collaborators for their effort during this